| Revista: | Gaceta médica de Caracas |
| Base de datos: | |
| Número de sistema: | 000596100 |
| ISSN: | 2739-0012 |
| Autores: | Królak-Uliska, Aneta1 Dobrovanov, Oleksandr2 |
| Instituciones: | 1Anaesthesiology and Intensive Care Unit, Hospital Wgrów, Wgrów, Poland., 2A. Getlik Clinic for Children and Adolescents, Slovak Medical University in Bratislava, Bratislava, Slovak Republic, |
| Año: | 2024 |
| Volumen: | 132 |
| Número: | 3 |
| Paginación: | 609-620 |
| País: | Venezuela |
| Idioma: | Español |
| Resumen en español | Gram-negative bacteria pose a significant threat as primary agents of infection in septic shock, a condition with high mortality rates in intensive care patients. To combat this, chemists develop antibiotic drugs fortified with protective agents, such as carbapenemase inhibitors, to counter bacterial resistance mechanisms. This study aims to evaluate the clinical efficacy of two antibiotic combinations, imipenem/cilastatin/relebactam (IMI/REL) and piperacillin/tazobactam (PIP/TAZ), in the treatment of septic shock caused by gram-negative bacteria. Seventeen patients diagnosed with septic shock were divided into Group 1 with IMI/REL and Group 2 with PIP/TAZ. All patients received antishock treatment, renal replacement therapy, and ventilation. Bacteriological detection identified four gram-negative pathogens in biological samples, with further phenotyping and genotyping confirming resistance mechanisms. |
| Palabras clave: | Antishock treatment, Acinetobacter baumannii, antibiotic therapy, genotyping, clinical effectiveness |
| Texto completo: | Texto completo (Ver PDF) Texto completo (Ver HTML) |
